EPO and chronic kidney disease: However, in line with the μCT data (Figure 4B-C and Figure S3D), cKD mice (without EPO stimulation) exhibited a 31% decrease in the expression of RANKL as compared to their genotypic controls (ΔΔCT 0.071[95% CI(0.056-0.086)] vs 0.049[95% CI(0.037-0.075)], respectively, Figure 5G).